11 Best Most Active Stocks To Buy According to Analysts

Page 8 of 10

3. Thermo Fisher Scientific Inc. (NYSE:TMO)

Number of Hedge Fund Holders: 101

Average Volume (3-Month): 2.71 million

Average Upside Potential as of June 20: 40.75%

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims to provide a fully integrated messenger ribonucleic acid (mRNA) solution to biopharmaceutical developers globally. The core objective of the collaboration is to accelerate the progression of candidate mRNA medicines from the research phase to clinical proof-of-concept.

The partnership will use Ethris’ advanced mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM RNA), minimal UTR, and mRNA manufacturing technologies. These will be combined with Thermo Fisher Scientific’s industry-leading end-to-end good manufacturing practice/GMP-compliant manufacturing capabilities.

Ethris’ platform technologies have already shown promising results. Specifically, the company’s lead candidate, ETH47, has shown favorable outcomes in Phase I trials. ETH47 is designed for local administration via nasal spray to target asthma exacerbations and showed dose-dependent and localized production of the encoded protein (interferon lambda) at the site of administration, with no systemic bioavailability.

The study confirmed the functional activity of the expressed protein by activating downstream signaling. The non-immunogenic nature of SNIM RNAs allows for repeated administration, which leads to sustained production of therapeutically active proteins within the human body. The technology is versatile, suitable for multiple routes of administration, and can be used to replace or augment missing or non-functional proteins, introduce new proteins to modulate disease, or develop vaccines.

Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. Ethris is a clinical-stage biotechnology company that has paved a new path from genes to therapeutic proteins.

Page 8 of 10